title: Pancreatic duct occlusion in the management of acute necrotizing pancreatitis in a canine model.
abstract: Based on results reported by others in using prolamine (Ethibloc; Ethicon Gmb H) to treat patients with chronic pancreatitis, without any observed pancreatic complications, we decided to use pancreatic duct occlusion experimentally in dogs in which we induced acute pancreatitis by the injection of calcium chloride into the pancreatic duct. This injection proved to be 100% lethal in the 5 animals constituting the control group, none of which were treated after the injection. Acute pancreatitis was then induced in 57 animals, also by injection of calcium chloride. These dogs were then treated with one of three substances that share the same physical properties: prolamine; Tissucol (Immuno AG, Vienna), a biologic tissue adhesive; silicone (Xantopren, Bayer Dental D-5090 Leverkusen). Thirty-seven dogs were treated with prolamine, 10 dogs with Tissucol, and 10 with silicone. The mortality rate in the 57 treated animals was 12.2%, compared to the 100% rate in the untreated control group. The mechanical action achieved by blocking the pancreatic duct shows how the evolution of acute pancreatitis at different stages could be modified. This specific treatment limits the pathophysiologic process of acute pancreatitis in dogs. These findings provide us with a promising outlook for the treatment of this severe illness.
authors: F
authors: F
authors: Torino
authors: O
authors: O
authors: Gil
authors: M
authors: M
authors: Garaycoechea
authors: H
authors: H
authors: Garcia
authors: A
authors: A
authors: Casavilla
authors: C
authors: C
authors: Shenk
authors: D
authors: D
authors: Hojman
mesh_terms: D000208:Acute Disease; D000818:Animals; D007611:Aprotinin / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004285:Dogs; D004338:Drug Combinations / Q000008:administration & dosage; D005176:Factor XIII / Q000008:administration & dosage*; D005260:Female; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen / Q000008:administration & dosage*; D008297:Male; D009336:Necrosis; D010183:Pancreatic Ducts; D010195:Pancreatitis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010665:Phenylpropanolamine / Q000008:administration & dosage*; D012828:Silicones / Q000008:administration & dosage; D013917:Thrombin / Q000008:administration & dosage*; D014014:Tissue Adhesives / Q000008:administration & dosage*
chemical_list: D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D012828:Silicones; D014014:Tissue Adhesives; D010665:Phenylpropanolamine; D005340:Fibrinogen; D005176:Factor XIII; D007611:Aprotinin; D013917:Thrombin